PTIX (Protagenic Therapeutics) ROCE %: 0.00% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

PTIX Protagenic Therapeutics Inc PTIX
22 GF Score
Price $0.18
! 2 Warning Signs
View Full Analysis

What is Protagenic Therapeutics ROCE %?

Protagenic Therapeutics PTIX +8.02% 22 ROCE % is 0.00% as of Dec. 2025. GuruFocus rates PTIX with a GF Score™ of 22/100. The stock has 2 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Protagenic Therapeutics's annualized ROCE % for the quarter that ended in Dec. 2025 was 0.00%.

Protagenic Therapeutics  (OTCPK:PTIX) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Protagenic Therapeutics ROCE % Related Terms

Protagenic Therapeutics ROCE % Historical Data

* Premium members only.

The historical data trend for Protagenic Therapeutics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Protagenic Therapeutics ROCE % Chart

Protagenic Therapeutics Annual Data
Trend Jun15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 -76.80 -39.80 -92.45 -236.06

Protagenic Therapeutics Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -717.78 -1,252.32 0.00 0.00 0.00
PTIX
22GF Score
Protagenic Therapeutics Inc PTIX
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Protagenic Therapeutics ROCE % Calculation

Protagenic Therapeutics's annualized ROCE % for the fiscal year that ended in Dec. 2024 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2024 )  (A: Dec. 2023 )(A: Dec. 2024 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2024 )  (A: Dec. 2023 )(A: Dec. 2024 )
=-5.525/( ( (4.323 - 0.655) + (1.956 - 0.943) )/ 2 )
=-5.525/( (3.668+1.013)/ 2 )
=-5.525/2.3405
=-236.06 %

Protagenic Therapeutics's ROCE % of for the quarter that ended in Dec. 2025 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Dec. 2025 )  (Q: Sep. 2025 )(Q: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Dec. 2025 )  (Q: Sep. 2025 )(Q: Dec. 2025 )
=-3.7/( ( (5.003 - 9.703) + (4.431 - 6.824) )/ 2 )
=-3.7/( ( -4.7 + -2.393 )/ 2 )
=-3.7/-3.5465
=0 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 0.00% mean?
Protagenic Therapeutics (PTIX) has a ROCE % of 0.00% as of Dec. 2025.
Is Protagenic Therapeutics' ROCE % too high?
Protagenic Therapeutics' current ROCE % is 0.00%. Overall, Protagenic Therapeutics has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Protagenic Therapeutics' ROCE % compare to CERO and CYTOF?
Protagenic Therapeutics' ROCE % of 0.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Protagenic Therapeutics's current ROCE % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Protagenic Therapeutics stock overvalued right now?
Protagenic Therapeutics (PTIX) has a current ROCE % of 0.00%. The current ROCE % is 0.00%. Protagenic Therapeutics' overall GF Score™ is 22/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Protagenic Therapeutics (PTIX), the current ROCE % is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Protagenic Therapeutics Business Description

Address 149 Fifth Avenue, Suite 500, New York, NY, USA, 10010
Protagenic Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. It provides treatments for mood, anxiety, depression, and neurodegenerative disorders by using peptide-based and brain-active therapeutics. The company's main compound, PT00114, is a synthetic form of Teneurin Carboxy-terminal Associated Peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. It has also created a portfolio of novel neuropeptides that are in various stages of development and preclinical evaluation for the treatment of mood disorders.
22GF Score

Get the complete analysis for PTIX

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.18
Price